Thursday’s Top Medical & Biotech Stocks

By admin | March 28, 2008

Submitted by BioHealth Investor Blog

by H.S. Ayoub
BioHealth Investor

Subscribe now to keep up to date on the latest news, articles and daily top stocks:

Subscribe by Email
Subscribe by Feed

Biotechnology

IMMUNOSYN CORPORATIN [IMYN.OB] +19.90%
BIOSANTE PHARMA INC [BPAX] +19.88%
TITAN PHARMA INC [TTP] +14.17%
REXAHN PHARMACEUTICL [RXHN.OB] +13.64%
ANESIVA INC [ANSV] +10.00%

Diagnostic Substances

IMMUCELL CP [ICCC] +25.02%
TORREYPINES THERAPEU [TPTX] +18.32%
REMOTEMDX INC [RMDX.OB] +10.37%
AVANT IMMUNOTHERAPEU [AVAND] +9.92%
ISTA PHARMACTLS [ISTA] +8.50%

Drug Delivery

COLUMBIA LABS INC [CBRX] +3.77%
FLAMEL TECH SA ADR [FLML] +2.99%
BIOVAIL CORP [BVF] +1.49%
PENWEST PHARM CO [PPCO] +1.15%
NEKTAR THERAPEUTIC [NKTR] +1.00%

Drug Manufacturers

GEOPHARMA INC [GORX] +12.77%
NEUROGESX, INC. [NGSX] +11.21%
MAP PHARMACEUTICALS, [MAPP] +9.65%
SIGA TECH INC [SIGA] +9.50%
PROVECTUS PHARMA [PVCT.OB] +9.09%

Drug Related Products

ARGAN INC [AGX] +5.37%
DRAXIS HEALTH INC [DRAX] +3.39%
PERRIGO COMPANY [PRGO] +2.56%
AUXILIUM PHARMACEUT [AUXL] +2.40%
SCHIFF NUTRIT INTL [WNI] +2.05%

Generic Drugs

HELICOS BIOSCIENCES [HLCS] +1.00%
CATALYST PHARMACEUTI [CPRX] +0.79%

Medical Appliances & Equipment

FONAR CORP [FONR] +19.75%
SOMANETICS CORP [SMTS] +8.45%
ENDOCARE INC [ENDO] +8.33%
ESCALON MED CP [ESMC] +6.91%
LANGER INC [GAIT] +5.15%

Medical Instruments & Supplies

OCULUS INNOVATIVE SC [OCLS] +30.53%
NANOSPHERE, INC. [NSPH] +27.39%
RETRACTABLE TECH INC [RVP] +22.54%
ORTHOVITA INC [VITA] +13.30%
SAFESTITCH MEDICAL, [SFES.OB] +9.09%

Medical Laboratories & Research

SPHERIX INC [SPEX] +13.89%
PSYCHEMEDICS NEW [PMD] +2.44%
ERESEARCHTECHNOLOG [ERES] +1.97%
RADNET INC [RDNT] +1.33%
BIO-REFERENCE LAB [BRLI] +1.14%

BioHealth Investor.com

Rating 3.00 out of 5
[?]

We don't know every stock and we want to know your thoughts. Register on Biotech Stocks Blog now and get published within minutes. Before posting, it is recommended that you review our posting guidelines.

Comments